Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual antihuman epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high...
Gespeichert in:
| Veröffentlicht in: | Journal of breast cancer 2021, 24(4), 102, pp.359-366 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 366 |
|---|---|
| container_issue | 4 |
| container_start_page | 359 |
| container_title | Journal of breast cancer |
| container_volume | 24 |
| creator | Ha, Joo Young Kim, Jeong Eun Lee, Hee Jin Jeong, Jae Ho Ahn, Jin-Hee Jung, Kyung Hae Gong, Gyungyub Chae, Eun Young Kim, Hak Hee Chung, Il Yong Ko, Beom Seok Kim, Sung-Bae |
| description | Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual antihuman epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.
Methods: A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade ( 20% TILs).
Results: In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).
Conclusion: HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer. |
| doi_str_mv | 10.4048/jbc.2021.24.e36 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8410619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2559434868</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-b291027f4ae17b43577538d30d0efdd71cc28ef1e94c0a72a49a8ec09437ced93</originalsourceid><addsrcrecordid>eNqNUktv1DAQjhCIlsKZq48gNlvHdh6-IJWlj5VWUFXL2XKcSdfbxA62s2X5S_xJnO6qEjdOM5a_hz3zJcn7DM8ZZtX5tlZzgkk2J2wOtHiRnBLMSco5xi-T06ykVVqUeXGSvPF-i3HBaFm-Tk4ooznhtDxN_qzH3rp0aVrdBSeDNvdote-HjVX7AB5pg27GXhp0OegGXC87dO3sY9igK6mCdegOFAxTQ9Jb63XQO0BfHEgf0EIaBQeE3k3C38DKZjvupAnoq1UQ5C_oZhHnajt0k_kMrV2kjr-jZz1D0jToFtzx_DZ51crOw7tjPUt-XF2uFzfp6vv1cnGxSlWcSUhrwjNMypZJyMo6_rQsc1o1FDcY2qYpM6VIBW0GnCksSyIZlxUozONwFDScniUfD7rGteJBaWGlfqr3Vjw4cXG3Xgpe5QUmecR-PmCHse6hUWDiFDsxON1Lt39i_ntj9Cbq7ETFMlxkk9mHo4CzP0fwQfTaK-g6acCOXpA8jw9jVVFF6PkBqpz13kH7bJNhMcVBxDiIKQ6CMBHjEBmfDoxHqG3rlYa4kWcWjoHgBFecxg5nEV39P3qhQ1yYNQs7mkD_AmTHzI0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2559434868</pqid></control><display><type>article</type><title>Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab</title><source>KoreaMed Synapse</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>KoreaMed Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Ha, Joo Young ; Kim, Jeong Eun ; Lee, Hee Jin ; Jeong, Jae Ho ; Ahn, Jin-Hee ; Jung, Kyung Hae ; Gong, Gyungyub ; Chae, Eun Young ; Kim, Hak Hee ; Chung, Il Yong ; Ko, Beom Seok ; Kim, Sung-Bae</creator><creatorcontrib>Ha, Joo Young ; Kim, Jeong Eun ; Lee, Hee Jin ; Jeong, Jae Ho ; Ahn, Jin-Hee ; Jung, Kyung Hae ; Gong, Gyungyub ; Chae, Eun Young ; Kim, Hak Hee ; Chung, Il Yong ; Ko, Beom Seok ; Kim, Sung-Bae</creatorcontrib><description>Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual antihuman epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.
Methods: A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade (<= 20% TILs, > 20% TILs).
Results: In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).
Conclusion: HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.</description><identifier>ISSN: 1738-6756</identifier><identifier>EISSN: 2092-9900</identifier><identifier>DOI: 10.4048/jbc.2021.24.e36</identifier><identifier>PMID: 34352937</identifier><language>eng</language><publisher>SEOUL: Korean Breast Cancer Soc</publisher><subject>Life Sciences & Biomedicine ; Oncology ; Original ; Science & Technology ; 일반외과학</subject><ispartof>Journal of Breast Cancer, 2021, 24(4), 102, pp.359-366</ispartof><rights>2021 Korean Breast Cancer Society 2021 Korean Breast Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>5</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000692089300001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c404t-b291027f4ae17b43577538d30d0efdd71cc28ef1e94c0a72a49a8ec09437ced93</citedby><cites>FETCH-LOGICAL-c404t-b291027f4ae17b43577538d30d0efdd71cc28ef1e94c0a72a49a8ec09437ced93</cites><orcidid>0000-0001-5588-8332 ; 0000-0002-4860-4458 ; 0000-0003-3996-7596 ; 0000-0001-7831-7874 ; 0000-0002-3478-6721 ; 0000-0002-4963-6603 ; 0000-0001-5743-0712 ; 0000-0002-2956-9212 ; 0000-0001-5271-8530 ; 0000-0002-8749-2612 ; 0000-0001-9766-1531 ; 0000-0002-1580-7224</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410619/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410619/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2115,27929,27930,39263,53796,53798</link.rule.ids><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002750334$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Ha, Joo Young</creatorcontrib><creatorcontrib>Kim, Jeong Eun</creatorcontrib><creatorcontrib>Lee, Hee Jin</creatorcontrib><creatorcontrib>Jeong, Jae Ho</creatorcontrib><creatorcontrib>Ahn, Jin-Hee</creatorcontrib><creatorcontrib>Jung, Kyung Hae</creatorcontrib><creatorcontrib>Gong, Gyungyub</creatorcontrib><creatorcontrib>Chae, Eun Young</creatorcontrib><creatorcontrib>Kim, Hak Hee</creatorcontrib><creatorcontrib>Chung, Il Yong</creatorcontrib><creatorcontrib>Ko, Beom Seok</creatorcontrib><creatorcontrib>Kim, Sung-Bae</creatorcontrib><title>Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab</title><title>Journal of breast cancer</title><addtitle>J BREAST CANCER</addtitle><description>Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual antihuman epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.
Methods: A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade (<= 20% TILs, > 20% TILs).
Results: In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).
Conclusion: HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.</description><subject>Life Sciences & Biomedicine</subject><subject>Oncology</subject><subject>Original</subject><subject>Science & Technology</subject><subject>일반외과학</subject><issn>1738-6756</issn><issn>2092-9900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNUktv1DAQjhCIlsKZq48gNlvHdh6-IJWlj5VWUFXL2XKcSdfbxA62s2X5S_xJnO6qEjdOM5a_hz3zJcn7DM8ZZtX5tlZzgkk2J2wOtHiRnBLMSco5xi-T06ykVVqUeXGSvPF-i3HBaFm-Tk4ooznhtDxN_qzH3rp0aVrdBSeDNvdote-HjVX7AB5pg27GXhp0OegGXC87dO3sY9igK6mCdegOFAxTQ9Jb63XQO0BfHEgf0EIaBQeE3k3C38DKZjvupAnoq1UQ5C_oZhHnajt0k_kMrV2kjr-jZz1D0jToFtzx_DZ51crOw7tjPUt-XF2uFzfp6vv1cnGxSlWcSUhrwjNMypZJyMo6_rQsc1o1FDcY2qYpM6VIBW0GnCksSyIZlxUozONwFDScniUfD7rGteJBaWGlfqr3Vjw4cXG3Xgpe5QUmecR-PmCHse6hUWDiFDsxON1Lt39i_ntj9Cbq7ETFMlxkk9mHo4CzP0fwQfTaK-g6acCOXpA8jw9jVVFF6PkBqpz13kH7bJNhMcVBxDiIKQ6CMBHjEBmfDoxHqG3rlYa4kWcWjoHgBFecxg5nEV39P3qhQ1yYNQs7mkD_AmTHzI0</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Ha, Joo Young</creator><creator>Kim, Jeong Eun</creator><creator>Lee, Hee Jin</creator><creator>Jeong, Jae Ho</creator><creator>Ahn, Jin-Hee</creator><creator>Jung, Kyung Hae</creator><creator>Gong, Gyungyub</creator><creator>Chae, Eun Young</creator><creator>Kim, Hak Hee</creator><creator>Chung, Il Yong</creator><creator>Ko, Beom Seok</creator><creator>Kim, Sung-Bae</creator><general>Korean Breast Cancer Soc</general><general>Korean Breast Cancer Society</general><general>한국유방암학회</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0001-5588-8332</orcidid><orcidid>https://orcid.org/0000-0002-4860-4458</orcidid><orcidid>https://orcid.org/0000-0003-3996-7596</orcidid><orcidid>https://orcid.org/0000-0001-7831-7874</orcidid><orcidid>https://orcid.org/0000-0002-3478-6721</orcidid><orcidid>https://orcid.org/0000-0002-4963-6603</orcidid><orcidid>https://orcid.org/0000-0001-5743-0712</orcidid><orcidid>https://orcid.org/0000-0002-2956-9212</orcidid><orcidid>https://orcid.org/0000-0001-5271-8530</orcidid><orcidid>https://orcid.org/0000-0002-8749-2612</orcidid><orcidid>https://orcid.org/0000-0001-9766-1531</orcidid><orcidid>https://orcid.org/0000-0002-1580-7224</orcidid></search><sort><creationdate>20210801</creationdate><title>Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab</title><author>Ha, Joo Young ; Kim, Jeong Eun ; Lee, Hee Jin ; Jeong, Jae Ho ; Ahn, Jin-Hee ; Jung, Kyung Hae ; Gong, Gyungyub ; Chae, Eun Young ; Kim, Hak Hee ; Chung, Il Yong ; Ko, Beom Seok ; Kim, Sung-Bae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-b291027f4ae17b43577538d30d0efdd71cc28ef1e94c0a72a49a8ec09437ced93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Life Sciences & Biomedicine</topic><topic>Oncology</topic><topic>Original</topic><topic>Science & Technology</topic><topic>일반외과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ha, Joo Young</creatorcontrib><creatorcontrib>Kim, Jeong Eun</creatorcontrib><creatorcontrib>Lee, Hee Jin</creatorcontrib><creatorcontrib>Jeong, Jae Ho</creatorcontrib><creatorcontrib>Ahn, Jin-Hee</creatorcontrib><creatorcontrib>Jung, Kyung Hae</creatorcontrib><creatorcontrib>Gong, Gyungyub</creatorcontrib><creatorcontrib>Chae, Eun Young</creatorcontrib><creatorcontrib>Kim, Hak Hee</creatorcontrib><creatorcontrib>Chung, Il Yong</creatorcontrib><creatorcontrib>Ko, Beom Seok</creatorcontrib><creatorcontrib>Kim, Sung-Bae</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Journal of breast cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ha, Joo Young</au><au>Kim, Jeong Eun</au><au>Lee, Hee Jin</au><au>Jeong, Jae Ho</au><au>Ahn, Jin-Hee</au><au>Jung, Kyung Hae</au><au>Gong, Gyungyub</au><au>Chae, Eun Young</au><au>Kim, Hak Hee</au><au>Chung, Il Yong</au><au>Ko, Beom Seok</au><au>Kim, Sung-Bae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab</atitle><jtitle>Journal of breast cancer</jtitle><stitle>J BREAST CANCER</stitle><date>2021-08-01</date><risdate>2021</risdate><volume>24</volume><issue>4</issue><spage>359</spage><epage>366</epage><pages>359-366</pages><issn>1738-6756</issn><eissn>2092-9900</eissn><abstract>Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual antihuman epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.
Methods: A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade (<= 20% TILs, > 20% TILs).
Results: In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).
Conclusion: HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.</abstract><cop>SEOUL</cop><pub>Korean Breast Cancer Soc</pub><pmid>34352937</pmid><doi>10.4048/jbc.2021.24.e36</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-5588-8332</orcidid><orcidid>https://orcid.org/0000-0002-4860-4458</orcidid><orcidid>https://orcid.org/0000-0003-3996-7596</orcidid><orcidid>https://orcid.org/0000-0001-7831-7874</orcidid><orcidid>https://orcid.org/0000-0002-3478-6721</orcidid><orcidid>https://orcid.org/0000-0002-4963-6603</orcidid><orcidid>https://orcid.org/0000-0001-5743-0712</orcidid><orcidid>https://orcid.org/0000-0002-2956-9212</orcidid><orcidid>https://orcid.org/0000-0001-5271-8530</orcidid><orcidid>https://orcid.org/0000-0002-8749-2612</orcidid><orcidid>https://orcid.org/0000-0001-9766-1531</orcidid><orcidid>https://orcid.org/0000-0002-1580-7224</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1738-6756 |
| ispartof | Journal of Breast Cancer, 2021, 24(4), 102, pp.359-366 |
| issn | 1738-6756 2092-9900 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8410619 |
| source | KoreaMed Synapse; DOAJ Directory of Open Access Journals; PubMed Central Open Access; KoreaMed Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
| subjects | Life Sciences & Biomedicine Oncology Original Science & Technology 일반외과학 |
| title | Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T07%3A56%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor-Infiltrating%20Lymphocytes%20in%20Human%20Epidermal%20Growth%20Factor%20Receptor%202-Positive%20Breast%20Cancer%20Receiving%20Neoadjuvant%20Docetaxel,%20Carboplatin,%20Trastuzumab,%20and%20Pertuzumab&rft.jtitle=Journal%20of%20breast%20cancer&rft.au=Ha,%20Joo%20Young&rft.date=2021-08-01&rft.volume=24&rft.issue=4&rft.spage=359&rft.epage=366&rft.pages=359-366&rft.issn=1738-6756&rft.eissn=2092-9900&rft_id=info:doi/10.4048/jbc.2021.24.e36&rft_dat=%3Cproquest_pubme%3E2559434868%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2559434868&rft_id=info:pmid/34352937&rfr_iscdi=true |